Skip to content

Testing Feasibility of Care Coordination and Motivational Interviewing for Women With a Recent Preterm Birth

Feasibility Testing of Care Coordination and Motivational Interviewing for Women With a Recent Preterm Birth

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05120843
Enrollment
13
Registered
2021-11-15
Start date
2022-02-03
Completion date
2023-09-23
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contraceptive Usage, Depression, Health Care Utilization, Preterm Birth, Tobacco Use, Weight, Birth

Keywords

Preconception care, Interconception care, Postpartum care, Preventive health care, Care coordination, Motivational Interviewing

Brief summary

This study continues an adaptation of care coordination to address the needs of women after preterm birth. This is a small single arm open trial designed to test intervention implementation and refine the intervention before ongoing feasibility testing.

Detailed description

Interventionists will be trained in care coordination strategies and Motivational Interviewing (MI) techniques. Following training, investigators will enroll eligible women from a postpartum unit at a single hospital, or within two weeks of birth. Investigators will assess feasibility, adoption, reach, and fidelity of the intervention and of study data collections strategies. The intervention protocol will be revised to reflect these assessments.

Interventions

BEHAVIORALCare coordination and motivational interviewing

Interventionist will engage participants in care planning, health education, health care navigation, screening for unmet health needs or social needs, and motivational interviewing. The final intervention is expected to be six months in duration. However during this single-arm open testing phase, some participants may receive only key components of the intervention in order to assess feasibility, reach, adoption, and fidelity of those components.

Sponsors

Children's Hospital of Philadelphia
Lead SponsorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
University of Pennsylvania
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
14 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

1. Female 2. Less than 45 years old 3. History of preterm birth (\< 34 weeks gestational age or 34 - 36 weeks with identifiable risk factors for recurrent preterm birth which may include low preventive care utilization, tobacco use, obesity, depression or anxiety, or history of unmet contraceptive needs) 4. Intention to seek pediatric care at one of two pediatric primary care sites 5. Medicaid insurance

Exclusion criteria

1. History of sterilization procedure. 2. Plan to move away from the area or transfer pediatric primary care within six months of enrollment. 3. Limited English proficiency

Design outcomes

Primary

MeasureTime frameDescription
Screening Rate (Feasibility)Screening phase (Up to 1 week prior to enrollment)The study team will compare the number of potentially eligible participants to those who are screened for eligibility. The number screened will be defined as the number of people whose are reviewed to approach for enrollment. The number of potentially eligible participants will be considered the number of women with preterm births with Medicaid insurance.
Enrollment Rate (Feasibility)Screening phase (Up to one week prior to enrollment)The study team will track the proportion of eligible women approached for enrollment who enroll in the study.
Reasons for Non-participation (Acceptability)Screening phase (Up to 1 week prior to enrollment)For women who decline enrollment we will ask them, if they are willing, to provide reasons for non-participation and potential study modifications that might have encouraged them to participate. Responses will be tabulated and reviewed for potential themes.
Retention Rate (Feasibility)Enrollment through six monthsThe study team will track the proportion of enrolled participants who complete the intervention and the study assessments.
Number of Completed Assessments (Feasibility)Enrollment through six monthsThe study team will track the proportion of the baseline, 3-month, and 6-month assessments that are completed.
Care Coordination Fidelity (Feasibility)Enrollment through six monthsWe will assess the proportion of intervention components completed, including interventionist completion of screening tools, as well as other tasks outlined in the care plan, including focused education, navigation, and addressing barriers to care, screening.
Motivational Interviewing (MI) Fidelity (Feasibility)Enrollment through six monthsOnePass is a validated tool used to evaluate MI practice and assess fidelity based on review of a single session, using 23 items to assess MI components.61 This tool yields a global score while also identifying specific areas for additional practice and training. Scores range from 1 - 7 with 5 considered a minimum for competence. Interventionists will complete at least one OnePass within a month of starting MI sessions with participants.

Secondary

MeasureTime frameDescription
Change in Autonomy SupportBaseline and 3 monthsAutonomy support will be measured with the short form of the Health Care Climate Questionnaire (6 items, range 6 - 42, Cronbach alpha 0.82). Scores on the short form 6-item version are calculated by averaging the individual item scores. Higher average scores represent a higher level of perceived autonomy support.
Change in Autonomous MotivationBaseline and 6 monthsAutonomous motivation will be measured using the Autonomous Motivation and External Regulation scales of the Treatment Self-Regulation Questionnaire (10 items, range 7 - 70, Cronbach alpha 0.90) with a higher score indicating higher emotion regulation strategy.
Count of Preventive Care Visits6 monthsThis will include postpartum visits, visits for contraceptive management, routine preventive care visits, and visits to follow-up on complications of pregnancy (secondary prevention). Visits will be abstracted from the health record and from interventionist records.
Proportion of Recommended Care Completed6 monthsThis Outcome Measure reports the average percentage of the recommended care plan completed among participants. Recommended care will be abstracted from a care plan completed within the first two weeks after enrollment. Completed care will be abstracted from the health record and from interventionist records.

Countries

United States

Participant flow

Pre-assignment details

We have included a Table for the screening and enrollment phase of the study because a major goal of the study was to assess feasibility of screening and enrollment procedures, as well as reasons for non-participation. This table, and the numbers included in this table, support calculation of Outcomes 1 - 3. In addition they provide important information about feasibility that are relevant to other research in this area.

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
13 Participants
Age, Continuous29.4 years
STANDARD_DEVIATION 5.8
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
13 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Gestational age at delivery33.2 weeks
STANDARD_DEVIATION 3
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
13 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Region of Enrollment
United States
13 Participants
Sex: Female, Male
Female
13 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 13
other
Total, other adverse events
0 / 13
serious
Total, serious adverse events
0 / 13

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026